In this issue of the e-news

CONTENTS:

• A Treatment For Vaccine Induced Thrombotic Thrombocytopenia (VITT)/Thrombotic Thrombocytopenic Syndrome (TTS)
• Possible Reduced Vaccine Response In Immune Compromised Patients

In this issue of the e-news

CONTENTS:

• Making Life (And Treatment) Better For Patients With ITP
• Strategies for Managing Cyclic Thrombocytopenia
• Managing Immune Thrombocytopenia in Infants

In this issue of the e-news

CONTENTS:

• Sharing The Patient Perspective Of Unmet Needs In Among Families Living With Immune Thrombocytopenia
• Additional IVIG benefits During A Global Pandemic

In this issue of the e-News, we report on ongoing research about ITP and the COVID-19 virus and vaccine(s) being conducted by global experts in ITP, including several of PDSA’s Medical Advisors.

CONTENTS:

• Vaccine-Induced Immune Thrombotic Thrombocytopenia
• Thrombocytopenia Following COVID-19 Vaccine Exposure
• Platelet-Activating Immune Complexes In Patients Suspected To Have Heparin-Induced Thrombocytopenia (HIT) In Severe Cases Of COVID-19

In this issue of the e-news

CONTENTS:

• Screening for Genetic Mutations for the Early Diagnosis of Common Variable Immunodeficiency in Children With Refractory Immune Thrombocytopenia
• Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy

In this issue of the e-news, we report on research contributed to the 62nd ASH Annual Meeting and Exposition by PDSA staff and advisors in addition to research from external researchers showcasing patients’ overall quality of life living with ITP, a promising future ITP treatment, and risk factors for older ITP patients.

CONTENTS:

• Impact of Therapy Choice on Fatigue in Adults with Immune Thrombocytopenia
• Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia
• Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia

This year’s 62nd ASH Annual Meeting and Exposition was virtual due to the global pandemic. Held December 5-8, the meeting attracted thousands of clinicians, scientists, pharmaceutical company personnel and even investment analysts worldwide to share ground-breaking research in the field of hematology. In conjunction with the ASH meeting, PDSA hosted the annual Friday Morning ITP Breakfast , coordinated by PDSA and four of PDSA’s Medical Advisors, James Bussel, MD, Nichola Cooper, MD, Michele Lambert, MD and John Semple, PhD. This year’s virtual event featured fourteen hematology experts from seven countries who presented their leading-edge ITP research. In this issue of the e-news, we report on research contributed to by PDSA staff and advisors showcasing advanced knowledge on ITP therapies and patients’ overall quality of life living with ITP. Watch for additional ASH reports in the winter issue of The Platelet News, the PDSA quarterly newsletter.

CONTENTS:

• A Multicentre Randomized Trial of First-line Treatment Pathways For Newly Diagnosed Immune Thrombocytopenia: A Standard Steroid Treatment vs Combined Steroid and Mycophenolate (FLIGHT Trial)
• Decision Aid to Support Shared Decision Making in Pediatric Refractory Immune Thrombocytopenia
• Patient’s Reported Perceptions On Satisfaction with Immune Thrombocytopenia Treatments: Results from the ITP World Impact Survey (I-WISh)